Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials

Hormonal therapies for receptor positive-breast and prostate cancer patients have shown clinical efficacy but also several side effects including osteoporosis, loss of bone mass and increased fracture risk. Denosumab represents an anti RANKL (receptor activator of nuclear factor-kB ligand) monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Galvano, Antonio, Scaturro, Dalila, Badalamenti, Giuseppe, Incorvaia, Lorena, Rizzo, Sergio, Castellana, Luisa, Cusenza, Stefania, Cutaia, Sofia, Santini, Daniele, Guadagni, Fiorella, Roselli, Mario, Gori, Stefania, Latteri, Mario Adelfio, Bazan, Viviana, Giulia, Letizia Mauro, Russo, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700425/
https://www.ncbi.nlm.nih.gov/pubmed/31440444
http://dx.doi.org/10.1016/j.jbo.2019.100252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700425/
https://www.ncbi.nlm.nih.gov/pubmed/31440444
http://dx.doi.org/10.1016/j.jbo.2019.100252

Ejemplares similares